Memantine Tablet
Product Images NDC 72603-119

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine (NDC 72603-119). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Containerlabel10mg (Containerlabel10mg)

Label for Memantine Hydrochloride Tablets, USP 10 mg oral tablets by NorthStar Rx LLC. The label indicates a quantity of 60 tablets, with storage instructions and manufacturer information including NorthStar Rx LLC in Memphis, TN, and Dr. Reddy's Laboratories Limited in India. The label also shows an NDC number and barcode.*

FDA Label Image

Containerlabel5mg (Containerlabel5mg)

Label for Memantine Hydrochloride Tablets, USP 5 mg oral tablets. The label indicates a quantity of 60 tablets per container. It is branded by NorthStar Rx LLC and manufactured by Dr. Reddy's Laboratories Limited, India. Storage instructions specify controlled room temperature between 20°C to 25°C (68°F to 77°F). The label also features an NDC number and a barcode.*

FDA Label Image

Figure1 (Figure1)

A line graph depicting the mean change from baseline in ADCS-ADL scores over weeks of treatment comparing Memantine HCl and placebo groups. The graph shows clinical improvement and decline thresholds, with data points at multiple time intervals including 4, 12, and 28 weeks. Error bars indicate standard error of the mean (SEM).*

FDA Label Image

Figure2 (Figure2)

A cumulative percentage plot showing patient response comparing Memantine HCl and placebo groups. The X-axis represents the change from baseline in ADCS-ADL scores, and the Y-axis shows the cumulative percentage of patients. Data is plotted with Memantine HCl and placebo curves for comparison.*

FDA Label Image

Figure3 (Figure3)

A line graph showing mean change from baseline in SIB score over 28 weeks of treatment comparing Memantine HCl and Placebo. The graph displays clinical improvement and decline thresholds with error bars indicating SEM at specific time points.*

FDA Label Image

Figure4 (Figure4)

A line graph comparing the cumulative percentage of patients for two groups, Placebo and Memantine HCl, plotted against SIB (Severe Impairment Battery) change from baseline. The graph shows patient response trends over the SIB score changes with the Memantine HCl group reaching higher cumulative percentages at greater improvements compared to Placebo.*

FDA Label Image

Figure5 (Figure5)

A line graph showing mean change in ADAS-Cog scores from baseline over 24 weeks of treatment. Two groups are plotted: Placebo/Donepezil and Memantine HCl/Donepezil. The graph includes error bars and indicates clinical improvement and clinical decline thresholds on the y-axis.*

FDA Label Image

Figure6 (Figure6)

A cumulative percentage plot comparing the ADCS-ADL change from baseline between a placebo/donepezil group and a memantine HCl/donepezil group. The x-axis represents the ADCS-ADL change from baseline, and the y-axis shows the cumulative percentage of patients.*

FDA Label Image

Figure7 (Figure7)

A line graph showing mean change from baseline ADCS-ADL scale scores over weeks of treatment comparing Memantine HCl/Donepezil and Placebo/Donepezil groups. The graph illustrates clinical improvement and decline trends over a 24-week period with error bars for variability.*

FDA Label Image

Figure8 (Figure8)

A cumulative percentage curve graph comparing the effects of Memantine HCl/Donepezil versus Placebo/Donepezil on SIB (Severe Impairment Battery) change from baseline. The x-axis represents SIB change from baseline with negative values indicating improvement, and the y-axis represents the cumulative percentage of patients. The graph shows two plotted lines representing the two treatment groups.*

FDA Label Image

Structure (Structure)

Chemical structure of Memantine hydrochloride showing a bicyclic amine with methyl groups attached, as represented by the molecular diagram with NH2·HCl notation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.